Home
About
News & Events

News & Events

Nordic Bioscience launches new website

Congratulations! You have made it—since you are here, it means you have found your way to our new website. When creating this new page, we have set out with three goals in mind to provide the best user experience possible: our commitment to scientific clarity, user experience, and transparent access to our biomarker expertise. Some […]

Read article

PRESS RELEASE: Nordic Bioscience launches novel Endotrophin assay

The nordicEndotrophin™ high-precision sandwich assay is available on fully automated, high-accuracy, high-throughput platforms Herlev, May 16, 2025 – Nordic Bioscience introduces nordicEndotrophin™, a fully automated high-precision assay that selectively quantifies the intact 77-amino-acid Endotrophin signaling hormone—qualified in the CAP/CLIA certified Nordic Bioscience laboratory. When integrated with the company’s existing product line, the biomarker assay demonstrated prognostic […]

Read article

PRO-C3 Kit in a Box—15% introduction offer!

Now available! Get 15% off in this introductory offer. As of today, nordicPRO-C3™, our premier collagen formation, fibroblast activity, and fibrogenesis soluble biomarker is now available as a convenient, ready-to-use Kit in a Box from Nordic Bioscience. Elecsys PRO-C3 was recently launched as a CE marked assay on the Roche Cobas platform. To complement the […]

Read article

PRESS RELEASE: PRO-C3 launched by Roche Diagnostics

PRO-C3 launched by Roche Diagnostics on cobas analysers Herlev, May 6, 2025 – Nordic Bioscience announces that its PRO-C3 test is launched today by Roche Diagnostics on their cobas analysers. The Roche Elecsys® PRO-C3, used with the ADAPT formula (age, diabetes status, PRO-C3, platelets), assesses liver fibrosis severity – a disease responsible for approximately one in every […]

Read article

Nordic Bioscience receives CLIA Certification and expands lab capabilities with ELF

Nordic Bioscience is now CLIA Certified—we are expanding towards diagnostics and clinical decision making, including ELF capabilities. CLIA Certification Our Nordic laboratory is now CLIA Certified—expanding towards diagnostics and clinical decision making. While we have always maintained CLIA standards, our clinical laboratory is now officially CLIA certified, in addition to our longstanding CAP accreditation. This milestone reflects […]

Read article

Nordic Bioscience Holding A/S Annual Report 2024 Highlights: A Year of Remarkable Achievements

Nordic Bioscience Holding A/S Annual Report 2024 Highlights We are proud to present the highlights from our 2024 Annual Report, marking a year of significant milestones and outstanding performance at Nordic Bioscience. This year also marks our first-time adoption of full IFRS, reflecting our commitment to transparency and global standards. Scientific Excellence Our unique expertise […]

Read article

News

PRESS RELEASE: Nordic Bioscience receives Letter of Support from the FDA for the PRO-C3 biomarker in tumor fibrosis

June 12, 2023

Read article

Morten Karsdal, CEO of Nordic Bioscience, receives The Arthur D. Little Nordic Life Science Award

April 14, 2023

Read article

Pliant Therapeutics publishes positive data from their INTEGRIS-IPF Phase 2a trial of bexotegrast featuring PRO-C3 biomarker

January 24, 2023

Read article

Best Of 2022 Publications Digest

January 3, 2023

Read article

Madrigal Pharmaceuticals takes a major step toward improving the lives of patients with NASH with the help of the PRO-C3 biomarker

December 20, 2022

Read article

NEJM Evidence Study on PRO-C6 Followed Up By Two Editorials

September 30, 2022

Read article

1 … 3 4 5 6 7

Upcoming events

No upcoming events

Biomarker Solutions

Biomarker Portfolio

Why Biomarkers?

Cardiovascular diseases

Dermatology

Gastrointestinal diseases

Hepatic diseases

Kidney diseases

Neuroscience

Obesity

Oncology

Respiratory diseases

Rheumatic diseases

What we offer

Biomarker portfolio

Biomarker Solutions

Biomarker Portfolio

Why Biomarkers?

Our services

Lab solutions

Biomarker Solutions

Biomarker Portfolio

Why Biomarkers?

Measure specific protein fragments

Our technology

Biomarker Solutions

Biomarker Portfolio

Why Biomarkers?

About Nordic Bioscience

Who we are

Biomarker Solutions

Biomarker Portfolio

Why Biomarkers?

Cardiovascular diseases

Dermatology

Gastrointestinal diseases

Hepatic diseases

Kidney diseases

Neuroscience

Obesity

Oncology

Respiratory diseases

Rheumatic diseases

Biomarker Solutions

Biomarker Portfolio

Why Biomarkers?

Biomarker Solutions

Biomarker Portfolio

Why Biomarkers?

Biomarker Solutions

Biomarker Portfolio

Why Biomarkers?

News & Events

Nordic Bioscience launches new website

PRESS RELEASE: Nordic Bioscience launches novel Endotrophin assay

PRO-C3 Kit in a Box—15% introduction offer!

PRESS RELEASE: PRO-C3 launched by Roche Diagnostics

Nordic Bioscience receives CLIA Certification and expands lab capabilities with ELF

Nordic Bioscience Holding A/S Annual Report 2024 Highlights: A Year of Remarkable Achievements

News

PRESS RELEASE: Nordic Bioscience receives Letter of Support from the FDA for the PRO-C3 biomarker in tumor fibrosis

Morten Karsdal, CEO of Nordic Bioscience, receives The Arthur D. Little Nordic Life Science Award

Pliant Therapeutics publishes positive data from their INTEGRIS-IPF Phase 2a trial of bexotegrast featuring PRO-C3 biomarker

Best Of 2022 Publications Digest

Madrigal Pharmaceuticals takes a major step toward improving the lives of patients with NASH with the help of the PRO-C3 biomarker

NEJM Evidence Study on PRO-C6 Followed Up By Two Editorials

Upcoming events